Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

Source: 
Yahoo/Reuters
snippet: 

German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.